X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
YL-17231 has a broader activity than many current KRAS inhibitors and demonstrated strong inhibition of in vivo KRAS mutant xenograft tumor growth in our preclinical investigations.
Lead Product(s): YL-17231
Therapeutic Area: Oncology Product Name: YL-17231
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2023
Details:
TEB-17231 is a KRAS Inhibitor, it has shown robust tumor growth inhibition, against KRASG12V, KRASG12C, KRASG12D and other RAS mutant tumor cell lines. It is in preparation for phase1 studies for the treatment of KRAS-mutated cancer patients.
Lead Product(s): TEB-17231
Therapeutic Area: Oncology Product Name: TEB-17231
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Linperlisib (YY-20394) is a highly selective and potent PI3Kδ inhibitor that has shown a favorable safety profile, encouraging anti-tumor activities and promising PK and pharmaceutical properties as an oral once-a-day agent in late-stage clinical development.
Lead Product(s): Linperlisib
Therapeutic Area: Oncology Product Name: YY-20394
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2022
Details:
The collaborative approach will provide a steady stream of therapeutic candidates, YL-13027, for oncology clinical development, which the MD Anderson team, including David S. Hong, M.D., deputy chair of Investigational Cancer Therapeutics, will investigate.
Lead Product(s): Linperlisib
Therapeutic Area: Oncology Product Name: YY-20394
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 20, 2022
Details:
Linperlisib, a potent oral PI3Kδ inhibitor, had robust clinical activity with 79.5% ORR in relapsed or refractory Follicular Lymphoma. The safety data from the FL Phase 2 study indicated that linperlisib was generally safe and tolerable with manageable adverse events.
Lead Product(s): Linperlisib
Therapeutic Area: Oncology Product Name: YY-20394
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Yingli Pharma will grant Hengrui Medicine joint development rights and exclusive commercialization rights of PI3kδ inhibitor YY-20394 in Greater China.
Lead Product(s): Linperlisib
Therapeutic Area: Oncology Product Name: YY-20394
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jiangsu Hengrui Medicine
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
